Nucleic Acids for Potential Treatment of Rheumatoid Arthritis

Area of Science:

• Biotechnology
• Immunology
• Nanomedicine

Background:

• Rheumatoid arthritis (RA) is a prevalent systemic autoimmune disease impacting patient quality of life.
• Current RA treatments focus on symptom management and disease progression, with biological disease-modifying antirheumatic drugs (DMARDs) requiring prolonged treatment.
• Existing therapies have limitations, necessitating the exploration of novel therapeutic strategies.

Purpose of the Study:

• To review the therapeutic potential of nucleic acids in rheumatoid arthritis (RA) therapy and diagnosis.
• To summarize advancements in RNA interference (RNAi), nucleic acid aptamers, DNA nanostructures, and nucleic acid vaccines for RA.
• To discuss the future prospects of nucleic acid-based interventions for RA.

Main Methods:

• Literature review of therapeutic RNA applications in RA.
• Analysis of RNA interference (RNAi) mechanisms and efficacy for RA.
• Examination of nucleic acid aptamers, DNA nanostructures, and nucleic acid vaccines in RA context.

Main Results:

• Nucleic acids show potential as therapeutic agents and nanocarriers for RA.
• RNA interference (RNAi) offers targeted gene silencing for RA.
• Nucleic acid aptamers, DNA nanostructures, and vaccines present diverse strategies for RA treatment and diagnosis.

Conclusions:

• Nucleic acid-based therapies represent a promising frontier for rheumatoid arthritis (RA) management.
• Further research into RNAi, aptamers, DNA nanostructures, and vaccines can lead to innovative RA treatments.
• Bionanotechnology-driven nucleic acid therapeutics offer novel alternatives to combat RA effectively.